Anti-MUC2 [994/152]
Invented by Prof Lindy Durrant from University of Nottingham
Invented at University of Nottingham
- Datasheet
- References (4)
- Inventor Info
Info
| Catalogue Number | 151307 |
| Applications | ELISA IHC |
| Antigen/Gene or Protein Targets | Mucin2 (MUC2) |
| Reactivity | Human |
| Relevance | Mucins are a family of highly glycosylated, large molecular weight glycoproteins which are associated with many epithelial cells. MUC2 is the major intestinal mucin. O-glycans are attached to MUC2 in a potentially diverse arrangement, which is crucial for their interaction with endogenous and exogenous lectins. |
| Host | Mouse |
| Immunogen | A peptide based on the tandem repeat sequence of MUC2 |
| Positive Control | colon carcinoma |
| Subclass | IgG1 |
| Myeloma Used | NS0 |
| Recommended Growing Conditions | DMEM + 5% FCS |
| Notes | 944/152 is specific for Muc2 and will not detect Muc3 or Muc4. |
| Research Area | Cancer, Cell Type or Organelle Marker, Cell Signaling & Signal Transduction |
References: 4 entries
Gold et al. 2013. Mol Cancer. 12(1):143. PMID: 24257318.
ELISA
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
Europe PMC ID: 24257318
Durrant et al. 1994. Eur J Cancer. 30A(3):355-63. PMID: 8204359.
IHC
Production of monoclonal antibodies recognising the peptide core of MUC2 intestinal mucin.
Europe PMC ID: 8204359
Add a reference
References: 4 entries
Gold et al. 2013. Mol Cancer. 12(1):143. PMID: 24257318.
ELISA
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
Durrant et al. 1994. Eur J Cancer. 30A(3):355-63. PMID: 8204359.
IHC
Production of monoclonal antibodies recognising the peptide core of MUC2 intestinal mucin.
Add a reference
